Patent assignee · US · COMPANY

89bio, Inc.

🏢 View company profile →
16Patents
16Active
16Granted
54Portfolio score

Filing activity: Nov 30, 2015 → Nov 8, 2023

Most-cited patents

PatentTitleAreaCited byStatus
US10407479B2 Mutant FGF-21 peptide pegylated conjugates and uses thereof Human Necessities 7 Active
US10221135B2 1,4-substituted piperidine derivatives Emerging Cross-Sectional Technologies 5 Active
US11596669B2 Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates Chemistry; Metallurgy 3 Active
US10851057B2 1,4-substituted piperidine derivatives Emerging Cross-Sectional Technologies 3 Active
US11427623B1 Methods of treatment using mutant FGF-21 peptide conjugates Human Necessities 2 Active
US10919875B2 Substituted 4-benzyl and 4-benzoyl piperidine derivatives Chemistry; Metallurgy 2 Active
US11702388B2 1,4-substituted piperidine derivatives Emerging Cross-Sectional Technologies 1 Active
US11046707B2 Spiropiperidine derivatives Emerging Cross-Sectional Technologies 1 Active
US10874714B2 Method of treating fibroblast growth factor 21 (FGF-21) deficiency Human Necessities 1 Active
US11850275B2 Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates Chemistry; Metallurgy 1 Active
US12350314B2 Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates Chemistry; Metallurgy 0 Active
US11878966B2 Substituted 4-benzyl and 4-benzoyl piperidine derivates Chemistry; Metallurgy 0 Active
US12098130B2 1,4-substituted piperidine derivatives Emerging Cross-Sectional Technologies 0 Active
US12036284B2 Compositions and methods of treatment for severe hypertriglyceridemia Chemistry; Metallurgy 0 Active
US12037376B2 Methods of treatment using mutant FGF-21 peptide conjugates Human Necessities 0 Active
US11878982B2 Spiropiperidine derivatives Emerging Cross-Sectional Technologies 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.